| 36.62 -0.13 (-0.35%) | 08-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 43.79 | 1-year : | 51.15 |
| Resists | First : | 37.5 | Second : | 43.79 |
| Pivot price | 35.79  |
|||
| Supports | First : | 34.11 | Second : | 32.02 |
| MAs | MA(5) : | 36.9 |
MA(20) : | 35.21 |
| MA(100) : | 31.54 |
MA(250) : | 32.96 |
|
| MACD | MACD : | 0.9 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 84.3 |
D(3) : | 89 |
| RSI | RSI(14): 60.9 |
|||
| 52-week | High : | 40.71 | Low : | 27.55 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IMCR ] has closed below upper band by 32.9%. Bollinger Bands are 29.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 36.81 - 37.11 | 37.11 - 37.31 |
| Low: | 35.55 - 35.88 | 35.88 - 36.11 |
| Close: | 36.18 - 36.7 | 36.7 - 37.05 |
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized. Within oncology, Immunocore is progressing IMC-C103C through early-stage (Phase I/II) dose escalation trials for several solid tumor types, notably non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers. Another key oncology program, IMC-F106C, is also in Phase I/II dose escalation studies for a diverse array of solid malignancies, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. For infectious diseases, the company is advancing IMC-I109V in Phase I/II clinical trials for chronic hepatitis B virus, alongside IMC-M113V, which is undergoing preclinical development for human immunodeficiency virus (HIV). Additionally, Immunocore is developing novel therapeutic candidates designed to deliver precise, targeted immunosuppression as a treatment strategy for autoimmune conditions.
Fri, 21 Aug 2026
IMCR Looks 19.2% Undervalued on GF Value™ - GuruFocus
Mon, 17 Aug 2026
Is Immunocore Holdings (IMCR) Undervalued After Stronger Revenue And Profitability Results? - simplywall.st
Fri, 14 Aug 2026
How Investors May Respond To Immunocore (IMCR) Turning First-Half Profit Amid Recent Share Price Pullback - simplywall.st
Mon, 10 Aug 2026
IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum - Yahoo Finance
Fri, 07 Aug 2026
Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues - Yahoo Finance
Fri, 07 Aug 2026
Immunocore Holdings plc 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:IMCR) 2026-08-07 - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 52 (M) |
| Shares Float | 46 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 102.9 (%) |
| Shares Short | 8,220 (K) |
| Shares Short P.Month | 8,990 (K) |
| EPS | -0.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.14 |
| Profit Margin | -4.2 % |
| Operating Margin | -2.6 % |
| Return on Assets (ttm) | -0.2 % |
| Return on Equity (ttm) | -4.5 % |
| Qtrly Rev. Growth | 18.2 % |
| Gross Profit (p.s.) | 2.74 |
| Sales Per Share | 8.36 |
| EBITDA (p.s.) | 0.01 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -35 (M) |
| Levered Free Cash Flow | 36 (M) |
| PE Ratio | -101.73 |
| PEG Ratio | 0 |
| Price to Book value | 4.49 |
| Price to Sales | 4.37 |
| Price to Cash Flow | -53.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|